Guidance, NICE advice and quality standards in development | Guidance

Showing 131 to 140 of 300

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Itepekimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6547]	Technology appraisal guidance	TBC
Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]	Technology appraisal guidance	TBC
Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]	Technology appraisal guidance	TBC
Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]	Technology appraisal guidance	TBC
Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor [ID6305]	Technology appraisal guidance	TBC
Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]	Technology appraisal guidance	TBC
Lenacapavir for preventing HIV-1 in people aged 16 years or older [ID6495]	Technology appraisal guidance	11 March 2026
Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410]	Technology appraisal guidance	TBC
Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]	Technology appraisal guidance	TBC
Leriglitazone for treating andrenoleukodystrophy [ID3903]	Technology appraisal guidance	TBC